Hippo signalling maintains ER expression and ER breast cancer growth.
作者信息
Ma Shenghong, Wu Zhengming, Yang Feng, Zhang Jianmin, Johnson Randy L, Rosenfeld Michael G, Guan Kun-Liang
机构信息
Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
出版信息
Nature. 2021 Mar;591(7848):E1-E10. doi: 10.1038/s41586-020-03131-5. Epub 2021 Mar 3.
Abstract
摘要
相似文献
1
Hippo signalling maintains ER expression and ER breast cancer growth.河马信号通路维持雌激素受体表达及雌激素受体阳性乳腺癌生长。
Nature. 2021 Mar;591(7848):E1-E10. doi: 10.1038/s41586-020-03131-5. Epub 2021 Mar 3.
2
The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.河马激酶LATS1和LATS2通过与雌激素受体α相互作用来控制人类乳腺细胞的命运。
Nature. 2017 Jan 26;541(7638):541-545. doi: 10.1038/nature20829. Epub 2017 Jan 9.
3
TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.TGF-β 靶向 Hippo 通路支架 RASSF1A 以促进 YAP/SMAD2 核转位。
Mol Cell. 2016 Jul 7;63(1):156-66. doi: 10.1016/j.molcel.2016.05.012. Epub 2016 Jun 9.
4
Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER breast cancer.YAP 通过转录抑制雌激素受体 α，揭示 Hippo 通路是 ER 阳性乳腺癌的治疗靶点。
Nat Commun. 2022 Feb 25;13(1):1061. doi: 10.1038/s41467-022-28691-0.
5
Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.去泛素化酶USP9X通过LATS激酶和Hippo信号通路的核心组件抑制肿瘤生长。
Cancer Res. 2017 Sep 15;77(18):4921-4933. doi: 10.1158/0008-5472.CAN-16-3413. Epub 2017 Jul 18.
6
RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.RASSF1A 通过抑制 Hippo 激酶 LATS1 和 2 抑制雌激素受体 α（ERα）驱动的乳腺癌细胞生长。
Cells. 2021 Oct 24;10(11):2868. doi: 10.3390/cells10112868.
7
The molecular crosstalk of the hippo cascade in breast cancer: A potential central susceptibility.乳腺癌中 Hippo 级联的分子串扰：一个潜在的中心易感性。
Biochimie. 2024 Jul;222:132-150. doi: 10.1016/j.biochi.2024.03.008. Epub 2024 Mar 15.
8
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.梅林/NF2 缺失驱动的肿瘤发生与 CRL4(DCAF1)介导的 hippo 通路激酶 Lats1 和 2 在核内的抑制有关。
Cancer Cell. 2014 Jul 14;26(1):48-60. doi: 10.1016/j.ccr.2014.05.001.
9
The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.非受体酪氨酸激酶 c-Src 减弱了 SCF(β-TrCP) E3 连接酶的活性，从而阻止了 Taz 的蛋白酶体降解。
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1678-1683. doi: 10.1073/pnas.1610223114. Epub 2017 Feb 1.
10
LATS2 condensates organize signalosomes for Hippo pathway signal transduction.LATS2 凝聚体为 Hippo 通路信号转导组织信号复合物。
Nat Chem Biol. 2024 Jun;20(6):710-720. doi: 10.1038/s41589-023-01516-x. Epub 2024 Jan 10.
引用本文的文献
1
Atypical Hippo signaling network: uncovering novel insights into head and neck cancer biology and advancements in precision intervention.非典型河马信号网络：揭示头颈癌生物学的新见解及精准干预的进展
Front Cell Dev Biol. 2025 May 23;13:1610471. doi: 10.3389/fcell.2025.1610471. eCollection 2025.
2
Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein.微管相关丝氨酸/苏氨酸激酶3通过促进Yes相关蛋白的磷酸化介导的泛素化降解来抑制乳腺癌的恶性表型。
Breast Cancer Res. 2025 May 1;27(1):63. doi: 10.1186/s13058-025-02028-3.
3
The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2.河马通路效应因子YAP通过对抗ZHX2来抑制核因子-κB信号传导和肾透明细胞癌生长。
J Biol Chem. 2025 Mar 20;301(5):108430. doi: 10.1016/j.jbc.2025.108430.
4
The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.Yes相关蛋白在炎症性疾病和癌症中的作用。
MedComm (2020). 2025 Mar 10;6(3):e70128. doi: 10.1002/mco2.70128. eCollection 2025 Mar.
5
Cell signaling in infection and cancer: Parallels in pathogenesis.感染与癌症中的细胞信号传导：发病机制的相似之处
Front Cell Infect Microbiol. 2025 Feb 14;15:1539847. doi: 10.3389/fcimb.2025.1539847. eCollection 2025.
6
Decoding gene expression profiles of Hippo signaling pathway components in breast cancer.解析乳腺癌中Hippo信号通路成分的基因表达谱。
Mol Biol Rep. 2025 Feb 10;52(1):216. doi: 10.1007/s11033-025-10299-4.
7
WISP1 inhibition of YAP phosphorylation drives breast cancer growth and chemoresistance via TEAD4 activation.WISP1对YAP磷酸化的抑制通过激活TEAD4促进乳腺癌生长和化疗耐药。
Anticancer Drugs. 2025 Mar 1;36(3):157-176. doi: 10.1097/CAD.0000000000001687. Epub 2025 Jan 6.
8
LATS2 and FAT4 as key candidate genes of hippo pathway associated with the risk and progression of breast cancer: an in-silico approach.LATS2 和 FAT4 作为 hippo 通路相关的关键候选基因，与乳腺癌的风险和进展相关：一种计算机预测方法。
Sci Rep. 2024 Nov 21;14(1):28857. doi: 10.1038/s41598-024-79688-2.
9
Functional annotation of the Hippo pathway somatic mutations in human cancers.人类癌症中 Hippo 通路体细胞突变的功能注释。
Nat Commun. 2024 Nov 21;15(1):10106. doi: 10.1038/s41467-024-54480-y.
10
METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer.METTL14 抑制 YAP1 的表达和三阴性乳腺癌的干性。
J Exp Clin Cancer Res. 2024 Nov 20;43(1):307. doi: 10.1186/s13046-024-03225-2.
Zotero 插件